Shijiazhuang Yiling Pharmaceutical
Launch date
Employees
Market cap
€3.1b
Enterprise valuation
€3.1b (Public information from Sep 2024)
Share price
CNY14.59 002603.SZ
Shijiazhuang Hebei (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 8.8b | 10.1b | 12.5b | 10.3b | 10.4b | 11.7b | 13.2b |
| % growth | 51 % | 15 % | 24 % | (18 %) | 1 % | 13 % | 13 % |
| EBITDA | 1.8b | 2.0b | 3.4b | 2.3b | 2.4b | 2.3b | 2.6b |
| % EBITDA margin | 20 % | 20 % | 27 % | 23 % | 23 % | 20 % | 20 % |
| Profit | 1.2b | 1.3b | 2.4b | 1.4b | 1.3b | 1.5b | 1.8b |
| % profit margin | 14 % | 13 % | 19 % | 13 % | 13 % | 13 % | 14 % |
| EV / revenue | 3.5x | 3.2x | 3.9x | 3.8x | 2.4x | 2.1x | 1.8x |
| EV / EBITDA | 17.2x | 16.2x | 14.5x | 16.7x | 10.6x | 10.5x | 9.0x |
| R&D budget | 654m | 792m | 1.0b | 853m | - | - | - |
| R&D % of revenue | 7 % | 8 % | 8 % | 8 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
